Market Overview:
The global inhalation and nasal spray generic drugs market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of respiratory diseases, growing demand for cost-effective therapies, and rising preference for self-medication. In addition, the increasing geriatric population is also contributing to the growth of this market. Based on type, the global inhalation and nasal spray generic drugs market can be segmented into corticosteroids, bronchodilators, combinations, decongestant sprays, and others. The corticosteroids segment is expected to account for a major share of this market in 2018 owing to their high usage in asthma and COPD therapies. By application, the asthma segment is expected to dominate this market during the forecast period owing to its high prevalence across all regions worldwide.
Product Definition:
Inhalation is the process of breathing in, while nasal spray generic drugs are medications that are sprayed into the nose. Inhalers and nasal sprays are both types of generic drugs.
Generic drugs are medications that have been approved by the FDA as being equivalent to brand-name medications. This means that they have the same active ingredients, dosage form, and strength as the brand-name drug. Generic drugs usually cost less than brand-name drugs, because they don't have to cover the costs of research and development or advertising.
Inhalers and nasal sprays are both important because they allow people with respiratory problems to get relief from their symptoms without having to take medication orally or by injection. Inhalers can be used to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis.
Corticosteroids:
Corticosteroids are naturally occurring hormones that are produced by the adrenal glands in response to stress or anxiety. Corticosteroid drugs include a variety of medications used for the treatment of inflammation, immune system disorders, skin diseases, and psychiatric problems.
Bronchodilators:
Bronchodilators are substances that dilate or widen the bronchi in the lungs, thereby improving breathing. Bronchodilators may be administered orally (by mouth) or by injection. Some of the commonly used bronchodilators include beta-agonists (such as Albuterol), anti-inflammatory drugs (such as steroids), and local anesthetics.
Application Insights:
Asthma held the largest share of 42.1% in 2017 owing to the high incidence of asthma and other allergic rhinitis disorders. According to estimates from Global Asthma Report Card, published by Global Asthma Network, around 300 million people are suffering from asthma and another 1 billion have mild symptoms of the disease. In addition, according to data published by World Health Organization (WHO) in 2016, around 382 million people were diagnosed with COPD globally which was a rise of 6% since 2010 and it is expected that over 500 million people will be affected with COPD by 2050 globally. Thus these factors are anticipated to boost demand for inhalation drugs for asthma & other allergic rhinitis during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of respiratory disorders are some factors responsible for its growth. According to the data published by WebMD in 2018, around 20 million people suffer from COPD in U.S., out of which only 1% to 2% had received treatment for it. Thus, increasing awareness about generic inhalation and nasal spray drugs is expected to boost their usage rates over the forecast period.
Asia Pacific is expected to be one of the fastest-growing regions during the forecast period owing to rising healthcare expenditure levels coupled with growing patient awareness levels regarding these generic drugs and their benefits as compared to branded ones such as increased efficacy or decreased side effects associated with them (inhaler/nasal sprays). Moreover, government initiatives aimed at improving access & affordability are anticipated favorably impact market growth during this period 8).
Growth Factors:
- Increasing prevalence of respiratory diseases: The global prevalence of respiratory diseases is increasing due to the changing lifestyle and environmental factors. This is expected to drive the demand for inhalation and nasal spray generic drugs in the coming years.
- Growing awareness about benefits of generic drugs: There is a growing awareness among consumers about the benefits of using generic drugs, which is expected to boost the demand for inhalation and nasal spray generic drugs in the near future.
- Rising number of product approvals: The number of product approvals by regulatory authorities has been rising in recent years, which is likely to fuel growth prospects for inhalation and nasal spray generics market in coming years.
- Technological advancements: Technological advancements have led to development of new drug delivery systems such as dry powder inhalers (DPIs) that are more efficient than traditional metered dose inhalers (MDIs). This is anticipated to create opportunities for growth in the global market for inhalation and nasal spray generics over next few years . 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Inhalation and Nasal Spray Generic Drugs Market Research Report
By Type
Corticosteroids, Bronchodilators, Combinations, Decongestant Sprays, Others
By Application
Asthma, COPD, Allergic Rhinitis, Other
By Companies
Teva, Sandoz (Novartis AG), Mylan, Allergan PLC, Cipla, Akorn, Apotex, Sun Pharma (Ranbaxy), Nephron Pharma, Beximco Pharma, Hikma (Roxane), XIANJU PHARMA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Inhalation and Nasal Spray Generic Drugs Market Report Segments:
The global Inhalation and Nasal Spray Generic Drugs market is segmented on the basis of:
Types
Corticosteroids, Bronchodilators, Combinations, Decongestant Sprays, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Asthma, COPD, Allergic Rhinitis, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Sandoz (Novartis AG)
- Mylan
- Allergan PLC
- Cipla
- Akorn
- Apotex
- Sun Pharma (Ranbaxy)
- Nephron Pharma
- Beximco Pharma
- Hikma (Roxane)
- XIANJU PHARMA
Highlights of The Inhalation and Nasal Spray Generic Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Corticosteroids
- Bronchodilators
- Combinations
- Decongestant Sprays
- Others
- By Application:
- Asthma
- COPD
- Allergic Rhinitis
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Inhalation and Nasal Spray Generic Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Inhalation and nasal spray generic drugs are medications that are prescribed to treat specific conditions. Inhalation generic drugs are used to treat conditions such as asthma, COPD, and allergies. Nasal spray generic drugs are used to treat conditions such as colds, flu, and sinus infections.
Some of the major companies in the inhalation and nasal spray generic drugs market are Teva, Sandoz (Novartis AG), Mylan, Allergan PLC, Cipla, Akorn, Apotex, Sun Pharma (Ranbaxy), Nephron Pharma, Beximco Pharma, Hikma (Roxane), XIANJU PHARMA.
The inhalation and nasal spray generic drugs market is expected to register a CAGR of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Inhalation and Nasal Spray Generic Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Inhalation and Nasal Spray Generic Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Inhalation and Nasal Spray Generic Drugs Market - Supply Chain
4.5. Global Inhalation and Nasal Spray Generic Drugs Market Forecast
4.5.1. Inhalation and Nasal Spray Generic Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Inhalation and Nasal Spray Generic Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Inhalation and Nasal Spray Generic Drugs Market Absolute $ Opportunity
5. Global Inhalation and Nasal Spray Generic Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Type
5.3.1. Corticosteroids
5.3.2. Bronchodilators
5.3.3. Combinations
5.3.4. Decongestant Sprays
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Inhalation and Nasal Spray Generic Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Application
6.3.1. Asthma
6.3.2. COPD
6.3.3. Allergic Rhinitis
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Inhalation and Nasal Spray Generic Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Inhalation and Nasal Spray Generic Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Inhalation and Nasal Spray Generic Drugs Demand Share Forecast, 2019-2029
9. North America Inhalation and Nasal Spray Generic Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Application
9.4.1. Asthma
9.4.2. COPD
9.4.3. Allergic Rhinitis
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Type
9.7.1. Corticosteroids
9.7.2. Bronchodilators
9.7.3. Combinations
9.7.4. Decongestant Sprays
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Inhalation and Nasal Spray Generic Drugs Demand Share Forecast, 2019-2029
10. Latin America Inhalation and Nasal Spray Generic Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Application
10.4.1. Asthma
10.4.2. COPD
10.4.3. Allergic Rhinitis
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Type
10.7.1. Corticosteroids
10.7.2. Bronchodilators
10.7.3. Combinations
10.7.4. Decongestant Sprays
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Inhalation and Nasal Spray Generic Drugs Demand Share Forecast, 2019-2029
11. Europe Inhalation and Nasal Spray Generic Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Application
11.4.1. Asthma
11.4.2. COPD
11.4.3. Allergic Rhinitis
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Type
11.7.1. Corticosteroids
11.7.2. Bronchodilators
11.7.3. Combinations
11.7.4. Decongestant Sprays
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Inhalation and Nasal Spray Generic Drugs Demand Share, 2019-2029
12. Asia Pacific Inhalation and Nasal Spray Generic Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Application
12.4.1. Asthma
12.4.2. COPD
12.4.3. Allergic Rhinitis
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Type
12.7.1. Corticosteroids
12.7.2. Bronchodilators
12.7.3. Combinations
12.7.4. Decongestant Sprays
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Inhalation and Nasal Spray Generic Drugs Demand Share, 2019-2029
13. Middle East & Africa Inhalation and Nasal Spray Generic Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Application
13.4.1. Asthma
13.4.2. COPD
13.4.3. Allergic Rhinitis
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Inhalation and Nasal Spray Generic Drugs Market Size and Volume Forecast by Type
13.7.1. Corticosteroids
13.7.2. Bronchodilators
13.7.3. Combinations
13.7.4. Decongestant Sprays
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Inhalation and Nasal Spray Generic Drugs Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Inhalation and Nasal Spray Generic Drugs Market: Market Share Analysis
14.2. Inhalation and Nasal Spray Generic Drugs Distributors and Customers
14.3. Inhalation and Nasal Spray Generic Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Teva
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sandoz (Novartis AG)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Mylan
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Allergan PLC
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Cipla
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Akorn
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Apotex
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sun Pharma (Ranbaxy)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Nephron Pharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Beximco Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Hikma (Roxane)
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. XIANJU PHARMA
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
